Interplay of reverse transcriptase inhibitor therapy and gag p6 diversity in HIV type 1 subtype G and CRF02_AG

AIDS Research and Human Retroviruses

Volumn 24, Issue 9, 2008, Pages 1167-1174

  Ojesina, Akinyemi I ^a,g   Chaplin, Beth ^a   Sankalé, Jean Louis ^a   Murphy, Robert ^b   Idigbe, Emmanuel ^c   Adewole, Isaac ^d   Ekong, Ernest ^e   Idoko, John ^f   Kanki, Phyllis J ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NIGERIAN INSTITUTE OF MEDICAL RESEARCH   (Nigeria)

^d UNIVERSITY OF IBADAN   (Nigeria)

^e APIN Plus/Harvard PEPFAR   (Nigeria)

^f UNIVERSITY OF JOS   (Nigeria)

^g BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; THYMIDINE DERIVATIVE;

ARTICLE; BLOOD SAMPLING; CHROMATOGRAPHY; GAG P6 DIVERSITY; GENE MUTATION; GENE SEQUENCE; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; NIGERIA; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE INHIBITORS; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, DNA;

EID: 51849135719     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0308     Document Type: Article

References (37)

1. Yu XF, Matsuda Z, Yu QC, Lee TH, and Essex M: Role of the C terminus Gag protein in human immunodeficiency virus type 1 virion assembly and maturation. J Gen Virol 1995;76:3171-3179.
2. Huang M, Orenstein JM, Martin MA, and Freed EO: p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. J Virol 1995;69:6810-6818.
3. Gottlinger HG, Dorfman T, Sodroski JG, and Haseltine WA: Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc Natl Acad Sci USA 1991;88:3195-3199.
4. Demirov DG, Orenstein JM, and Freed EO: The late domain of human immunodeficiency virus type 1 p6 promotes virus release in a cell type-dependent manner. J Virol 2002;76:105-117.
5. Greene WC and Peterlin BM: Charting HIV's remarkable voyage through the cell: Basic science as a passport to future therapy. Nat Med 2002;8:673-680.
6. Xiang Y, Cameron CE, Wills JW, and Leis J: Fine mapping and characterization of the Rous sarcoma virus Pr76gag late assembly domain. J Virol 1996;70:5695-5700.
7. Yuan B, Li X, and Goff SP: Mutations altering the Moloney murine leukemia virus p12 Gag protein affect virion production and early events of the virus life cycle. EMBO J 1999;18:4700-4710.
8. Yasuda J and Hunter E: A proline-rich motif (PPPY) in the Gag polyprotein of Mason-Pfizer monkey virus plays a maturation-independent role in virion release. J Virol 1998;72:4095-4103.
9. Strack B, Calistri A, Accola MA, Palu G, and Gottlinger HG: A role for ubiquitin ligase recruitment in retrovirus release. Proc Natl Acad Sci USA 2000;97:13063-13068.
10. Strack B, Calistri A, Craig S, Popova E, and Gottlinger HG: AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding. Cell 2003;114:689-699.
11. Muller B, Patschinsky T, and Krausslich HG: The late-domain-containing protein p6 is the predominant phosphoprotein of human immunodeficiency virus type 1 particles. J Virol 2002;76:1015-1024.
12. Hemonnot B, Cartier C, Gay B, et al.: The host cell MAP kinase ERK-2 regulates viral assembly and release by phosphorylating the p6gag protein of HIV-1. J Biol Chem 2004;279:32426-32434.
13. Kennelly PJ and Krebs EG: Consensus sequences as substrate specificity determinants for protein kinases and protein phosphatases. J Biol Chem 1991;266:15555-15558.
14. Kondo E, Mammano F, Cohen EA, and Gottlinger HG: The p6gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles. J Virol 1995;69:2759-2764.
15. Checroune F, Yao XJ, Gottlinger HG, Bergeron D, and Cohen EA: Incorporation of Vpr into human immunodeficiency virus type 1: Role of conserved regions within the P6 domain of Pr55gag. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:1-7.
16. Kondo E and Gottlinger HG: A conserved LXXLF sequence is the major determinant in p6gag required for the incorporation of human immunodeficiency virus type 1 Vpr. J Virol 1996;70:159-164.
17. Lu YL, Bennett RP, Wills JW, Gorelick R, and Ratner L: A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles. J Virol 1995;69:6873-6879.
18. Marlowe N, Flys T, Hackett J Jr, Schumaker M, Jackson JB, and Eshleman SH: Analysis of insertions and deletions in the gag p6 region of diverse HIV type 1 strains. AIDS Res Hum Retroviruses 2004;20:1119-1125.
19. Flys T, Marlowe N, Hackett J, et al.: Analysis of PTAP duplications in the gag p6 region of subtype C HIV type 1. AIDS Res Hum Retroviruses 2005;21:739-741.
20. Yeni PG, Hammer SM, Hirsch MS, et al.: Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004;292:251-265.
21. Robinson LH, Gale CV, and Kleim JP: Inclusion of full length human immunodeficiency virus type 1 (HIV-1) gag sequences in viral recombinants applied to drug susceptibility phenotyping. J Virol Methods 2002;104:147-160.
22. Peters S, Munoz M, Yerly S, et al.: Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein. J Virol 2001;75:9644-9653.
23. Gallego O, de Mendoza C, Corral A, and Soriano V: Changes in the human immunodeficiency virus p7-p1-p6 gag gene in drug-naive and pretreated patients. J Clin Microbiol 2003;41:1245-1247.
24. Ojesina AI, Sankale JL, Odaibo G, et al.: Subtype-specific patterns in HIV Type 1 reverse transcriptase and protease in Oyo State, Nigeria: Implications for drug resistance and host response. AIDS Res Hum Retroviruses 2006;22:770-779.
25. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, and Higgins DG: The CLUSTAL_X windows interface: Flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 1997;25:4876-4882.
26. Maddison WP and Maddison DR: Interactive analysis of phylogeny and character evolution using the computer program MacClade. Folia Primatol (Basel) 1989;53:190-202.
27. Nijhuis M, Boucher CA, Schipper P, Leitner T, Schuurman R, and Albert J: Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. Proc Natl Acad Sci USA 1998;95:14441-14446.
28. Feher A, Weber IT, Bagossi P, et al.: Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites. Eur J Biochem 2002;269:4114-4120.
29. Soriano V and de Mendoza C: Genetic mechanisms of resistance to NRTI and NNRTI. HIV Clin Trials 2002;3:237-248.
30. Holguin A, Alvarez A, and Soriano V: Differences in the length of gag proteins among different HIV type 1 subtypes. AIDS Res Hum Retroviruses 2005;21:886-893.
31. Idigbe EO, Adewole TA, Eisen G, et al.: Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: A preliminary report on the Nigerian antiretroviral program. J Acquir Immune Defic Syndr 2005;40:65-69.
32. Yu XF, Dawson L, Tian CJ, Flexner C, and Dettenhofer M: Mutations of the human immunodeficiency virus type 1 p6Gag domain result in reduced retention of Pol proteins during virus assembly. J Virol 1998;72:3412-3417.
33. Dettenhofer M and Yu XF: Proline residues in human immunodeficiency virus type 1 p6(Gag) exert a cell type-dependent effect on viral replication and virion incorporation of Pol proteins. J Virol 1999;73:4696-4704.
34. Gurer C, Berthoux L, and Luban J: Covalent modification of human immunodeficiency virus type 1 p6 by SUMO-1. J Virol 2005;79:910-917.
35. Michalakis Y and Roze D: Evolution. Epistasis in RNA viruses. Science 2004;306:1492-1493.
36. Bonhoeffer S, Chappey C, Parkin NT, Whitcomb JM, and Petropoulos CJ: Evidence for positive epistasis in HIV-1. Science 2004;306:1547-1550.
37. Banerjee A, Dubnau E, Quemard A, et al.: inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994;263:227-230.